These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Biological factors influencing response to diuretics in patients with cirrhosis and ascites]. Lenaerts A, Codden T, Henry JP, Van Cauter J, Meunier JC, Ligny G. Gastroenterol Clin Biol; 2001 Mar; 25(3):268-72. PubMed ID: 11395674 [Abstract] [Full Text] [Related]
5. Short-term course of corticosteroids in the treatment of resistant ascites complicating schistosomal liver disease. el-Zayadi A, Mohran Z, Hasseeb N, Nagy N, Dabbous H. Am J Gastroenterol; 1991 Jan; 86(1):53-6. PubMed ID: 1986555 [Abstract] [Full Text] [Related]
6. Predictive factors influencing the therapeutic response to diuretic treatment of ascites in nonazotemic cirrhotic patients. Ljubicić N, Kujundzić M, Banić M, Vrkljan M. Scand J Gastroenterol; 1998 Apr; 33(4):441-7. PubMed ID: 9605268 [Abstract] [Full Text] [Related]
7. Factors predicting hyperkalemia in patients with cirrhosis receiving spironolactone. Abbas Z, Mumtaz K, Salam A, Jafri W. J Coll Physicians Surg Pak; 2003 Jul; 13(7):382-4. PubMed ID: 12887837 [Abstract] [Full Text] [Related]
9. A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients. Gatta A, Angeli P, Caregaro L, Menon F, Sacerdoti D, Merkel C. Hepatology; 1991 Aug; 14(2):231-6. PubMed ID: 1860680 [Abstract] [Full Text] [Related]
10. Spironolactone diuresis in patients with cirrhosis and ascites. Eggert RC. Br Med J; 1970 Nov 14; 4(5732):401-3. PubMed ID: 5481518 [Abstract] [Full Text] [Related]
11. Hydrochlorothiazide and spironolactone in hypertension. Schrijver G, Weinberger MH. Clin Pharmacol Ther; 1979 Jan 14; 25(1):33-42. PubMed ID: 363334 [Abstract] [Full Text] [Related]
12. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. Pérez-Ayuso RM, Arroyo V, Planas R, Gaya J, Bory F, Rimola A, Rivera F, Rodés J. Gastroenterology; 1983 May 14; 84(5 Pt 1):961-8. PubMed ID: 6339312 [Abstract] [Full Text] [Related]
15. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol; 1996 Oct 15; 78(8):902-7. PubMed ID: 8888663 [Abstract] [Full Text] [Related]
18. Hyperkalemic changes during spironolactone therapy for cirrhosis and ascites, with special reference to hyperkalemic intermittent paralysis. Radó JP, Marosi J, Szende L, Takó J. J Am Geriatr Soc; 1968 Aug 15; 16(8):874-86. PubMed ID: 5666934 [No Abstract] [Full Text] [Related]
19. Prediction of diuretic mobilization of cirrhotic ascites by pretreatment fractional sodium excretion. Knauf H, Wenk E, Schölmerich J, Goerg KJ, Gerok W, Leser HG, Mutschler E. Klin Wochenschr; 1990 Jun 05; 68(11):545-51. PubMed ID: 2198378 [Abstract] [Full Text] [Related]